Targeting AURKA with alisertib at a non-toxic concentration abolished BI-2536-induced BRCA1 and exerted a significant inhibitory effect on SCLC cells compared to BI-2536 alone, both in vitro and in vivo. This evidence concerns the gene BRCA1 and small cell lung carcinoma.